- Conditions
- Prostate Cancer
- Interventions
- fluciclovine (18F)
- Drug
- Lead sponsor
- Blue Earth Diagnostics
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 6
- States / cities
- San Diego, California • Atlanta, Georgia • Boston, Massachusetts + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–9
of 9
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Prostatic Neoplasms, Prostate Cancer, Recurrence
- Interventions
- [18F]CTT1057, [68Ga]Ga-PSMA-11
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Patients With Prostate Cancer
- Interventions
- Pelvic CT or MRI + MDP bone scan + or - 18F-NaF PET/CT(SOC)
- Diagnostic Test
- Lead sponsor
- Medhat Osman
- Federal
- Eligibility
- 18 Years to 89 Years · Male only
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Prostate Cancer
- Interventions
- Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2036
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 40 more
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Biochemical Recurrence of Malignant Neoplasm of Prostate
- Interventions
- Copper Cu 64 PSMA I&T
- Drug
- Lead sponsor
- Curium US LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 235 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 31
- States / cities
- Fullerton, California • Los Angeles, California • Newport Beach, California + 24 more
- Conditions
- Prostate Cancer
- Interventions
- Apalutamide, IHT
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate, Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Biochemical Recurrence (BCR), High-Risk Localized Prostate Cancer
- Interventions
- RYZ711, PSMA PET/CT
- Drug · Diagnostic Test
- Lead sponsor
- RayzeBio, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Recurrent, Prostate Cancer Metastatic
- Interventions
- 18F-DCFPyL, PET/CT Imaging
- Drug · Diagnostic Test
- Lead sponsor
- Progenics Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 13
- States / cities
- Duarte, California • Los Angeles, California • San Francisco, California + 10 more
- Conditions
- Biochemically Recurrent Prostate Cancer
- Interventions
- Darolutamide (BAY1841788, Nubeqa), Placebo matching darolutamide, ADT
- Drug · Other
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 985 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Duarte, California • Los Angeles, California + 18 more